To examine the histopathological features and treatment modalities in patients with uterine sarcoma according to subgroups (uterine leiomyosarcoma, low grade/high grade endometrial stromal sarcoma, adenosarcoma, undifferentiated uterine sarcoma) and to determine the factors affecting mortality rates. We retrospectively evaluated patients diagnosed with uterine sarcoma in our center between March 2012 and December 2019. We compared the clinicopathological characteristics and treatment modalities of the subgroups and investigated the factors affecting mortality rates using logistic regression analysis. There was no difference between the subgroups in terms of age, body mass index, menopausal status, comorbidity, presenting complaint, primary diagnosis, surgical treatment protocol, adnexal and lymph node involvement and tumor size (p> 0.01). However, there were higher rates of hormone therapy administration in the low grade endometrial stromal sarcoma group (p: 0.000). There were comparable rates of local and distant metastases between subgroups, however, no difference was found between chemotherapy and radiotherapy protocols (p> 0.01). It was found that in all US groups, stage was the only parameter which affected mortality rates (OR: 15.7 (95% CI 2.8-29.6) p = 0.002). Stage is the most important factor affecting mortality in all uterine sarcomas. Despite their different histopathological features, subgroups do not have distinctive features such as demographic features, presenting complaints, primary diagnosis and surgical treatment protocols.
Key words: Uterine sarcomas, adenosarcoma, leiomyosarcoma, endometrial stromal sarcomas, undifferentiated uterine sarcomas